Removal of Remdesivir’s Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Care for Critically Ill Patients With COVID-19

(2020) Srinivas Murthy et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Development and validation of a UHPLC-MS/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2/COVID-19 and Ebola virus disease

(2020) Valeria Avataneo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence

(2020) Yu-chen Cao et al.   Travel Medicine and Infectious Disease

Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19

(2020) Massimo Tempestilli et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

(2020) Mandeep R Mehra et al.   LANCET

Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment

(2018) Randall K. Hoover et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of sulfobutylether- -cyclodextrin (SBECD) in subjects on hemodialysis

(2011) D. R. Luke et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION